Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin rejuvenation. In addition, the company offers GenesisPlus system, a laser product for use in the temporary increase of clear nails in patients with onychomycosis, as well as for the treatment of fine wrinkles, diffuse redness, and rosacea; and CoolGlide, as well as myQ, a third-party sourced system for the Japanese market. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:CUTR
CUSIPN/A
Phone415-657-5500
Debt
Debt-to-Equity RatioN/A
Current Ratio2.08
Quick Ratio1.25
Price-To-Earnings
Trailing P/E Ratio55.81
Forward P/E Ratio76.40
P/E Growth3.77
Sales & Book Value
Annual Sales$151.49 million
Price / Sales3.92
Cash Flow$0.8963 per share
Price / Cash48.59
Book Value$4.68 per share
Price / Book9.31
Profitability
EPS (Most Recent Fiscal Year)$0.77
Net Income$29.99 million
Net Margins18.54%
Return on Equity16.12%
Return on Assets9.87%
Miscellaneous
Employees367
Outstanding Shares13,630,000
Market Cap$586.28
Cutera (NASDAQ:CUTR) Frequently Asked Questions
What is Cutera's stock symbol?
Cutera trades on the NASDAQ under the ticker symbol "CUTR."
How will Cutera's stock buyback program work?
Cutera announced that its board has approved a stock buyback program on Tuesday, August 8th 2017, which authorizes the company to buyback $25,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued.
How were Cutera's earnings last quarter?
Cutera, Inc. (NASDAQ:CUTR) issued its earnings results on Tuesday, May, 8th. The medical device company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.03. The medical device company earned $34.10 million during the quarter, compared to the consensus estimate of $35.27 million. Cutera had a net margin of 18.54% and a return on equity of 16.12%. The firm's quarterly revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.07) EPS. View Cutera's Earnings History.
When is Cutera's next earnings date?
What guidance has Cutera issued on next quarter's earnings?
Cutera issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $1.03-1.11 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.05. The company issued revenue guidance of $178-181 million, compared to the consensus revenue estimate of $179.02 million.
What price target have analysts set for CUTR?
5 brokers have issued 1 year price targets for Cutera's stock. Their forecasts range from $47.00 to $60.00. On average, they expect Cutera's share price to reach $54.00 in the next year. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Ratings for Cutera.
What is the consensus analysts' recommendation for Cutera?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Cutera stock?
Here are some recent quotes from research analysts about Cutera stock:
- 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (7/10/2018)
- 2. Gabelli analysts commented, "As a leading laser dermatology company, Cutera is an attractive long-term investment as management focuses on execution, growing sales and improving operating performance. Throughout 2017, Cutera revamped several members of its management team, including its CEO and CFO, along with several new hires to build out its sales and operational infrastructure in the US and internationally. Management is putting in place new processes to improve upon product development and scale up its organization for sustainable growth." (2/16/2018)
- 3. Maxim Group analysts commented, "3Q17 total revenue of $38.2M, up 26.1% y/y, was above both our estimate of $35.6M and consensus of $34.7M. North America product revenue grew 57.4% y/y, while international product revenue grew just 0.1% y/y." (11/8/2017)
Who are some of Cutera's key competitors?
Some companies that are related to Cutera include CONMED (CNMD), AxoGen, Inc Common Stock (AXGN), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), BioLife Solutions (BLFS), Vision Sciences (CGNT), Rockwell Medical (RMTI), Fonar (FONR), Helius Medical Technologies (HSDT), Second Sight Medical Products (EYES), Edap Tms (EDAP), Zynex Inc. common stock (ZYXI), Semler Scientific (SMLR) and Viveve Medical (VIVE).
Who are Cutera's key executives?
Cutera's management team includes the folowing people:
- Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 47)
- Mr. Ronald J. Santilli, Exec. Officer (Age 58)
- Mr. James A. Reinstein, CEO, Pres & Director (Age 53)
- Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 52)
- Dr. Michael Karavitis Ph.D., Exec. VP & Chief Technology Officer
Has Cutera been receiving favorable news coverage?
News headlines about CUTR stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cutera earned a media sentiment score of 0.11 on Accern's scale. They also gave news coverage about the medical device company an impact score of 48.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Cutera's major shareholders?
Cutera's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (2.69%), Summit Creek Advisors LLC (1.00%), Essex Investment Management Co. LLC (0.85%), Scout Investments Inc. (0.66%) and Bank of Montreal Can (0.32%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber, Miguel Pardos, Ronald J Santilli and Timothy J Oshea. View Institutional Ownership Trends for Cutera.
Which institutional investors are buying Cutera stock?
CUTR stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Essex Investment Management Co. LLC, Scout Investments Inc. and Summit Creek Advisors LLC. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett and James A Reinstein. View Insider Buying and Selling for Cutera.
How do I buy shares of Cutera?
Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cutera's stock price today?
One share of CUTR stock can currently be purchased for approximately $43.55.
How big of a company is Cutera?
Cutera has a market capitalization of $586.28 million and generates $151.49 million in revenue each year. The medical device company earns $29.99 million in net income (profit) each year or $0.77 on an earnings per share basis. Cutera employs 367 workers across the globe.
How can I contact Cutera?
Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]
MarketBeat Community Rating for Cutera (NASDAQ CUTR)
MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
